CO2019013554A2 - Composiciones de fármaco mejoradas de liberación extendida y altamente cargadas - Google Patents
Composiciones de fármaco mejoradas de liberación extendida y altamente cargadasInfo
- Publication number
- CO2019013554A2 CO2019013554A2 CONC2019/0013554A CO2019013554A CO2019013554A2 CO 2019013554 A2 CO2019013554 A2 CO 2019013554A2 CO 2019013554 A CO2019013554 A CO 2019013554A CO 2019013554 A2 CO2019013554 A2 CO 2019013554A2
- Authority
- CO
- Colombia
- Prior art keywords
- drug
- component
- carbomer
- extended release
- drug compositions
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 7
- 229940079593 drug Drugs 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000013265 extended release Methods 0.000 title 1
- 229920002125 Sokalan® Polymers 0.000 abstract 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 abstract 3
- 229960001631 carbomer Drugs 0.000 abstract 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- 229920000148 Polycarbophil calcium Polymers 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 229920001519 homopolymer Polymers 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229950005134 polycarbophil Drugs 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La tecnología divulgada proporciona composiciones de fármaco mejoradas que proporcionan una mayor estabilidad, un mayor potencial de carga de fármaco y propiedades de disolución de fármaco adecuadas, y métodos para prepararlas. La composición incluye: (a) un componente de fármaco que comprende una cantidad terapéuticamente eficaz de un fármaco; (b) un componente de liberación prolongada que comprende un polímero de ácido poliacrílico reticulado que es un homopolímero de carbómero, copolímero de carbómero, interpolímero de carbómero, policarbofilo o una mezcla de estos; y (c) un componente amortiguador que comprende un agente amortiguador que contiene magnesio; en donde el componente de fármaco constituye al menos 50% en peso de la composición.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762500078P | 2017-05-02 | 2017-05-02 | |
PCT/US2018/030380 WO2018204317A1 (en) | 2017-05-02 | 2018-05-01 | Improved extended release highly loaded drug compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019013554A2 true CO2019013554A2 (es) | 2020-04-01 |
Family
ID=62200552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0013554A CO2019013554A2 (es) | 2017-05-02 | 2019-11-29 | Composiciones de fármaco mejoradas de liberación extendida y altamente cargadas |
Country Status (12)
Country | Link |
---|---|
US (2) | US20200113839A1 (es) |
EP (1) | EP3618813B1 (es) |
JP (1) | JP7132947B2 (es) |
KR (1) | KR20190139942A (es) |
CN (1) | CN110709068B (es) |
BR (1) | BR112019022896A2 (es) |
CA (1) | CA3062158A1 (es) |
CO (1) | CO2019013554A2 (es) |
ES (1) | ES2924236T3 (es) |
IL (1) | IL270273B2 (es) |
PE (1) | PE20191795A1 (es) |
WO (1) | WO2018204317A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109839460A (zh) * | 2019-03-14 | 2019-06-04 | 上海海虹实业(集团)巢湖今辰药业有限公司 | 一种阿莫西林有关物质的检测方法 |
CN110824066B (zh) * | 2019-12-09 | 2022-05-20 | 北京悦康科创医药科技股份有限公司 | 一种头孢噻肟钠有关物质的检测方法 |
JP7300725B2 (ja) * | 2020-02-27 | 2023-06-30 | 日新製薬株式会社 | 固形製剤及びその製造方法 |
CN112986435B (zh) * | 2021-02-23 | 2022-08-05 | 海南通用三洋药业有限公司 | 一种注射用氨苄西林钠舒巴坦钠有关物质的测定方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2798053A (en) | 1952-09-03 | 1957-07-02 | Goodrich Co B F | Carboxylic polymers |
GB831897A (en) * | 1957-07-08 | 1960-04-06 | Bristol Myers Co | Antacid preparation and process for making same |
CH606154A5 (es) | 1974-07-02 | 1978-11-15 | Goodrich Co B F | |
US4267103A (en) | 1978-12-07 | 1981-05-12 | The B. F. Goodrich Company | Solvent polymerization of carboxyl containing monomers |
US4664915A (en) * | 1981-07-01 | 1987-05-12 | Bristol-Myers Company | Compressed and formed alkaline component suitable for use in buffered aspirin product |
US5288814A (en) | 1992-08-26 | 1994-02-22 | The B. F. Goodrich Company | Easy to disperse polycarboxylic acid thickeners |
US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
JP4454985B2 (ja) * | 2002-08-08 | 2010-04-21 | 第一三共株式会社 | 血液脂質を低下させるための医薬組成物 |
WO2004069234A1 (en) * | 2003-02-05 | 2004-08-19 | Ipca Laboratories Limited | Pharmaceutical compositions and process of production thereof |
WO2005123045A2 (en) * | 2004-06-10 | 2005-12-29 | Glatt Air Techniques, Inc. | Controlled release matrix pharmaceutical dosage formulation |
FR2879930B1 (fr) * | 2004-12-23 | 2007-08-31 | Oralance Pharma Sa | Nouveau systeme galenique pour le transport d'actif, procede de preparation et utilisation |
US20090124702A1 (en) * | 2005-01-25 | 2009-05-14 | Pechetti Siva Satya Krishna Babu | Pharmaceutical Compositions of Metformin |
EP1843761B1 (en) * | 2005-01-27 | 2018-01-31 | Alembic Limited | Extended release formulation of levetiracetam |
EP1901720A2 (en) * | 2005-06-23 | 2008-03-26 | Spherics, Inc. | Improved dosage forms for movement disorder treatment |
EP1906932A2 (en) * | 2005-06-29 | 2008-04-09 | Panacea Biotec Ltd. | Modified release pharmaceutical compositions on the basis of two polymers and processes thereof |
CA2653011A1 (en) * | 2008-12-03 | 2010-06-03 | Apotex Technologies Inc | Method and apparatus for packaging and dispensing pharmaceuticals |
US20120219623A1 (en) * | 2009-10-02 | 2012-08-30 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions comprising bi-1356 and metformin |
TWI636783B (zh) * | 2012-04-18 | 2018-10-01 | 友霖生技醫藥股份有限公司 | 含匹伐他汀(pitavastatin)穩定配方的醫藥組合物 |
WO2015110962A1 (en) * | 2014-01-21 | 2015-07-30 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and linagliptin or salts thereof |
-
2018
- 2018-05-01 JP JP2019560166A patent/JP7132947B2/ja active Active
- 2018-05-01 CA CA3062158A patent/CA3062158A1/en active Pending
- 2018-05-01 KR KR1020197033339A patent/KR20190139942A/ko not_active Application Discontinuation
- 2018-05-01 WO PCT/US2018/030380 patent/WO2018204317A1/en active Search and Examination
- 2018-05-01 BR BR112019022896A patent/BR112019022896A2/pt active Search and Examination
- 2018-05-01 CN CN201880034506.0A patent/CN110709068B/zh active Active
- 2018-05-01 US US16/609,912 patent/US20200113839A1/en not_active Abandoned
- 2018-05-01 PE PE2019002279A patent/PE20191795A1/es unknown
- 2018-05-01 ES ES18725989T patent/ES2924236T3/es active Active
- 2018-05-01 EP EP18725989.0A patent/EP3618813B1/en active Active
-
2019
- 2019-10-29 IL IL270273A patent/IL270273B2/en unknown
- 2019-11-29 CO CONC2019/0013554A patent/CO2019013554A2/es unknown
-
2021
- 2021-09-29 US US17/489,137 patent/US20220016035A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3062158A1 (en) | 2018-11-08 |
IL270273A (es) | 2019-12-31 |
EP3618813A1 (en) | 2020-03-11 |
PE20191795A1 (es) | 2019-12-24 |
US20220016035A1 (en) | 2022-01-20 |
CN110709068A (zh) | 2020-01-17 |
ES2924236T3 (es) | 2022-10-05 |
EP3618813B1 (en) | 2022-07-06 |
US20200113839A1 (en) | 2020-04-16 |
CN110709068B (zh) | 2022-11-08 |
KR20190139942A (ko) | 2019-12-18 |
JP2020518614A (ja) | 2020-06-25 |
WO2018204317A1 (en) | 2018-11-08 |
IL270273B1 (en) | 2023-03-01 |
IL270273B2 (en) | 2023-07-01 |
BR112019022896A2 (pt) | 2020-05-19 |
JP7132947B2 (ja) | 2022-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019013554A2 (es) | Composiciones de fármaco mejoradas de liberación extendida y altamente cargadas | |
CL2018000299A1 (es) | Composiciones con potenciadores de impregnacion para el suministro de fármacos. | |
BRPI0615860B8 (pt) | composição farmacêutica de liberação prolongada monolítica sólida | |
DOP2017000294A (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
NZ723859A (en) | Pharmaceutical compositions of therapeutically active compounds and their uses | |
EA201792345A1 (ru) | Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями | |
BR112016017352A2 (pt) | copolímeros termoassociativos e permutáveis, composições que os compreendem | |
NZ723860A (en) | Pharmaceutical compositions of therapeutically active compounds and their uses | |
ECSP17085669A (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
BR112019003945A2 (pt) | composições oftálmicas | |
BR112016001544A8 (pt) | composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório | |
BR112017006406A2 (pt) | composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico | |
MX2020010899A (es) | Inhibidor de bromodominio. | |
EA201992328A1 (ru) | Фармацевтическая композиция, содержащая ленватиниба мезилат | |
SA518400220B1 (ar) | تركيبة بوليمر تشتمل على بولي (ميثيل ميثاكريلات) وتركيبة معدلة التأثير | |
CR20170142A (es) | Composiciones farmacéuticas resistentes al abuso | |
MX2020007293A (es) | Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr. | |
MX2018008868A (es) | Composiciones farmaceuticas que contienen glucomanano con liberacion extendida y propiedades disuasivas de abuso. | |
CL2017003350A1 (es) | Composiciones farmacéuticas sólidas para el tratamiento del vhc | |
MX2019014666A (es) | Composicion farmaceutica que comprende un conjugado de anticuerpo contra c-met-farmaco y uso del mismo. | |
BR112017000462A2 (pt) | detergente para lavar louça de pastilha e métodos para a fabricação e uso do mesmo | |
BR112019001544A2 (pt) | composições poliméricas expansíveis em bloco | |
ECSP22054240A (es) | Compuesto y composici?n como inhibidor de quinasa del receptor pdgf | |
WO2018234871A3 (en) | COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE | |
PH12018500132A1 (en) | Solid pharmaceutical compositions for treating hcv |